BioTime expands OpRegen dry-AMD trial with U.S. sites

BioTime Inc. (NYSE:BTX) said today that it expanded its OpRegen Phase I/IIa trial into the U.S. with 2 new trial sites. The company’s study is evaluating its OpRegen cell therapy in patients with advanced dry form age-related macular degeneration.

The 2 U.S.-based trial sites will include ophthalmologists Dr. David Boyer from the Retina-Vitreous Associates Medical Group and Dr. Richard McDonald from the West Coast Retina Medical Group.

Get the full story at our sister site, Drug Delivery Business News.

The post BioTime expands OpRegen dry-AMD trial with U.S. sites appeared first on MassDevice.

from MassDevice http://ift.tt/2mjbkaz